



Attention News/Business Editors:

**NEW CHAIR OF CMC MICROSYSTEMS BRINGS LEADERSHIP IN
MICROSYSTEMS TECHNOLOGIES AND STRATEGIC PARTNERSHIPS**

KINGSTON, ONTARIO, December 7, 2005 - CMC Microsystems (CMC) is pleased to announce that Chris Lumb, President and CEO of Micralyne Inc., will serve as Chairman of CMC's Board of Directors. His guidance will be instrumental as CMC implements its strategic plan for 2005-2010 to accelerate the development of new Canadian-made microsystems for all sectors of the economy.

Mr. Lumb, P.Eng., an Alberta entrepreneur with strong linkages to Canada's university community, was selected Chairman of the CMC Board. Mr. Lumb has served as a Director of CMC for nine years and has played a key role in facilitating CMC's nation-wide delivery of microsystems technologies for research, development and commerce.

"We are very proud to have Mr. Lumb as Chairman, as CMC accelerates Canadian competitiveness in the microsystems era," says Dr. Brian Barge, President and CEO of CMC Microsystems. "His leadership and expertise in MEMS (Microelectromechanical Systems) and microfluidics will help to advance CMC's microsystems agenda, enabling researchers and developers to combine individual technologies for the creation of 'systems' that can be designed, manufactured, tested and successfully marketed to companies around the world."

Mr. Lumb graduated from the University of Waterloo with a Bachelor of Applied Science in Chemical Engineering in 1982. He has contributed to all aspects of Micralyne's development, and led its transition from a non-profit to a privately held company, generating revenue growth of 25% per year for the last five years.

Today, Micralyne is one of North America's leading commercial MEMS companies, with a portfolio that includes emission sensors used in most North American-made Ford automobiles,

devices for the printing/publishing industry, optical telecommunications switching devices, and implantable medical devices for drug delivery.

Mr. Lumb commented, “As Chairman of the CMC Board I look forward to supporting the organization’s strong role in developing the microsystem industry in Canada. Through the support of CMC Microsystems, research in this field is flourishing, allowing companies like Micralyne to be innovative and create world class technologies.”

Mr. Lumb replaces CMC’s outgoing Chairman, Dr. Ian McWalter, former President and CEO of Gennum Corporation. “Dr. McWalter’s distinguished contribution as Chair over the past 12 years has helped to build Canada’s microsystems community, and to guide CMC’s evolution as we prepare to address the new opportunities and challenges of the microsystems era,” says Dr. Barge.

- 30 -

For more information, contact:

Sonya Shorey
Senior Manager of Communications
CMC Microsystems
Tel: 613.530.4698
Cell: 613.851.9416
E-mail: shorey@cmc.ca

About CMC Microsystems

CMC Microsystems builds partnerships among government, industry and universities to enable and accelerate Canada’s global competitiveness in microsystems. As Canada’s leader in the provision of nationally-distributed infrastructure for microsystems research and technology development, CMC provides leading-edge tools and technologies for world-class research leading to innovation and commercialization of microsystems.

Established in 1984, CMC is a non-profit corporation funded by the Natural Sciences and Engineering Research Canada (NSERC), with matching contributions from industry in the form of technology, services and cash. CMC also manages major grants from the Canada Foundation for Innovation (CFI) and the Ontario Innovation Trust (OIT) through Queen’s University, and administers additional funds from the provinces of Québec and Manitoba. CMC's membership includes 42 universities, one college, and 29 industrial organizations. More information is available at www.cmc.ca

About Micralyne

Micralyne develops and manufactures microfabricated and MEMS (Micro-Electro-Mechanical-Systems)-based products. Micralyne is one of a handful of independent companies in the world that manufactures MEMS in high volumes. MEMS technology is built on the premise of making

industrial components smaller, faster and less expensive and facilitates radical improvements in the miniaturization of electronic and mechanical devices. These types of devices are used in many industries including communications, automotive, aerospace, and life sciences. More specifically, Micralyne's micron-scale solutions (i.e. 1000 microns = 1 millimetre) are found in emission sensors for Ford automobiles, optical switching technology in telecommunication networks, lab-on-a-chip devices for drug discovery, and commercial press equipment for printing today's most popular magazines. Micralyne, founded in 1982 and privatized in 1998, is a profitable and growing company headquartered in Edmonton, Alberta, Canada.

About Microsystems Technologies

Microsystems are small and powerful devices that sense and analyze their environment; make decisions using their built-in, miniature, and electronic brain; and then take action to help us in our daily lives. They are all around us – in cell phones, air bags, security systems, hearing aids, pacemakers, water quality systems – and in many other products we rely on.

Microsystems include microelectronics, micromechanics (usually implemented in the form of microelectromechanical systems or MEMS), microfluidics, photonics/optoelectronics, embedded software and progressively nano-scale phenomenon.

MEMS or Microelectromechanical Systems are small devices manufactured with dimensions of less than one millimeter (1000 microns), and with parts as small as 1 micron. For comparison, a human hair is 100 microns thick and bacteria are 1-2 microns long. Common MEMS applications include medical sensors, airbags in automobiles, aerospace navigation systems, and even ink jet printers.

Microfluidic-based microchips (*lab-on-a-chip*), allow minute volumes of liquids or gases to be pumped along a channel for quick and easy testing. These miniature labs can perform tasks such as DNA analysis or the separation of human blood cells, leading to more accurate diagnoses, improved treatments, and faster development of disease-fighting drugs.